




**Fig S1. Paxillin<sup>fl/fl</sup>cre mammary glands do not have altered stalk length or number of TEBs.** (A) Whole mount staining of 6 week old mammary gland. Arrowheads indicate terminal end buds (TEBs). Stalk length was measured in the indicated white boxed area. The box was drawn 1mm from lymph node with a 2 mm width. Scale bar: 2 mm. (B) Quantification of TEB number, n=9. (C) Quantification of stalk length, n=3. A Student's T-test was performed. Data represent mean ± s.e.m. ns=not significant.




**Fig S2. Paxillin<sup>fl/fl</sup>cre mammary glands have mislocalized active  $\beta 1$  integrin and reduced laminin deposition.** (A) 6 week old mammary gland sections stained for active  $\beta 1$  integrin. Scale bar: 50  $\mu$ m. (B) Quantification of basal membrane versus total duct active  $\beta 1$  integrin staining, n=4. (C) Mammary gland sections stained for laminin and  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA). Scale bar: 50  $\mu$ m. (D) Quantification of laminin intensity normalized to  $\alpha$ -SMA, n=3. (E) Mammary epithelial cell lysates blotted for phosphor-FAK and total FAK. (F) Quantification of pFAK level (normalized to total FAK), n=2. (G) Quantification of total FAK level (normalized to total actin), n=2. A Student's T-test was performed. Data represent mean  $\pm$  s.e.m. \* $<0.05$ , \*\* $<0.01$ .




**Fig S3. Paxillin<sup>fl/fl</sup>cre mammary glands do not have altered cell proliferation or apoptosis.** (A) Paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre ducts and terminal end buds (TEBs) stained with Ki67 and for cytokeratin-8 (CK8). Scale bar: 50  $\mu$ m. (B) Quantification of Ki67-positive cells, n=3 (C) Paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre ducts and TEBs stained for cleaved-caspase 3 and CK8. Scale bar: 50  $\mu$ m. (D) Quantification of cleaved-caspase 3-positive cells, n=3. A Student's T-test was performed. Data represent mean  $\pm$  s.e.m. ns=not significant.



**Fig S4. Total microtubule content is not noticeably perturbed in the paxillin<sup>fl/fl</sup>cre mammary gland.** (A) 6 week old mammary glands co-stained with acetylated tubulin and α-tubulin. Scale bar: 50 μm. (B) Quantification of mean fluorescence intensity of α-tubulin, n=3 (at least 5 ducts per animal). A Student's T-test was performed. Data represent mean ± s.e.m. ns=not significant.




**Fig S5. MyoVb and Rab11 protein levels in the paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre mammary gland.** (A) Mammary epithelial cell lysates blotted for MyoVb and Rab11. (B) Quantification of MyoVb level (adjusted to actin), n=2. (C) Quantification of Rab11 level (adjusted to actin), n=3. A Student T-test was performed. Data represent mean  $\pm$  s.e.m. \* $<0.05$ , \*\* $<0.01$ .




**Fig S6. Paxillin<sup>fl/fl</sup>cre acini lack a central lumen.** (A) Day 6 acini stained for ZO1 (green), E-cadherin (red) and DAPI (blue). Arrowheads indicate small lumens. Scale bar: 5  $\mu$ m. (B) Quantification of different types of lumen, n=2 (total of 85-126 acini per genotype were counted in each experiment). One-way ANOVA with Tukey's multiple comparisons test was performed for statistical analysis. Data represent mean  $\pm$  s.e.m. \* $<0.05$ , \*\* $<0.01$ .





**Fig S7. Paxillin<sup>fl/fl</sup>cre fail to accumulate apical FM4-64.** (A) Paxillin expression pattern in acini. Scale bar: 10  $\mu$ m. (B) Montage images of FM4-64 dye uptake experiments for paxillin<sup>+/+</sup>;cre and paxillin<sup>fl/fl</sup>;cre acini. Asterisk indicates the lumen, arrowhead points to apically accumulated FM4-64 dye. Scale bar: 10  $\mu$ m.




**Fig S8. Tubacin treatment rescues apical MT acetylation in paxillin<sup>fl/fl</sup>cre acini. (A)**

Confocal images of acini taken at the same laser power. The bottom of each confocal image shows a representative line profile graph through a single cell. Scale bar: 10 μm.


**(B)** Quantification of fluorescence intensity of acetylated-tubulin at the apical surface (or the center of paxillin<sup>fl/fl</sup>cre acini). **(C)** Quantification of fluorescence intensity of acetylated-tubulin at the basal surface. 5 acini for each condition, at least 5 cells per acinus were included in line profile analysis. One-way ANOVA with Tukey's multiple comparisons test was performed for statistical analysis. Data represent mean ± s.e.m.

\* < 0.05, \*\* < 0.01.







**Fig S9. Tubacin and blebbistatin treatment of paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre organoids.** (A) Phase images of blebbistatin-treated paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre organoids. Scale bar: 50  $\mu$ m. (B) Quantification of "hyper-branching" in blebbistatin-treated organoids, n=4. A Student's T-test was performed. Data represent mean  $\pm$  s.e.m. \* $<0.05$ , \*\* $<0.01$ , \*\*\* $<0.001$ . (C) DMSO and tubacin-treated organoids stained for paxillin. Scale bar: 20  $\mu$ m.




**Fig S10. Titration of paclitaxel and nocodazole treatment for organoid branching morphogenesis. (A)** Phase images of paclitaxel-treated paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre organoids. Scale bar: 50  $\mu$ m. **(B)** Quantification of branching, n=2 (total of 19-49 organoids per treatment were counted). A Student's T-test was performed. Data represent mean  $\pm$  s.e.m. \* $<0.05$ , \*\* $<0.01$ , \*\*\* $<0.001$ . **(C)** Phase images of nocodazole-treated paxillin<sup>+/+</sup>cre and paxillin<sup>fl/fl</sup>cre organoids. Scale bar: 50  $\mu$ m.




**Movie 1.** Z-stack movie of paxillin<sup>+/+</sup>;cre acini. Acini stained for GM130 (red), acetylated-tubulin (green) and DAPI (blue). Scale bar: 10  $\mu$ m.




**Movie 2.** Z-stack movie of paxillin<sup>fl/fl</sup>;cre acini. Acini stained for GM130 (red), acetylated-tubulin (green) and DAPI (blue). Scale bar: 10  $\mu$ m.




**Movie 3.** Z-stack movie of paxillin<sup>+/+</sup>;cre acini. Acini stained with phalloidin (red) and DAPI (blue). Scale bar: 10  $\mu$ m.



**Movie 4.** Z-stack movie of paxillin<sup>fl/fl</sup>;cre acini. Acini stained with phalloidin (red) and DAPI (blue). Scale bar: 10  $\mu$ m.




**Movie 5.** Z-stack movie of paxillin<sup>+/+</sup>;cre early stage acini. Acini stained with phalloidin (red) and DAPI (blue). Scale bar: 10  $\mu$ m.




**Movie 6.** Z-stack movie of paxillin<sup>fl/fl</sup>;cre early stage acini. Acini stained with phalloidin (red) and DAPI (blue). Scale bar: 10  $\mu$ m.






**Movie 7.** Branching morphogenesis assay. Paxillin<sup>+/+</sup>;cre organoid embedded in Matrigel. Imaged for 22 hours. Scale bar: 50  $\mu$ m. Timescale: min.




**Movie 8.** Branching morphogenesis assay. Paxillin<sup>fl/fl</sup>;cre organoid embedded in Matrigel. Imaged for 22 hours. Scale bar: 50  $\mu$ m. Timescale: min.





**Movie 9.** Branching morphogenesis assay. Paxillin<sup>fl/fl</sup>;cre organoid embedded in Matrigel and treated with DMSO. Imaged for 20 hours. Scale bar: 100  $\mu$ m. Timescale: min.



**Movie 10.** Branching morphogenesis assay. Paxillin<sup>fl/fl</sup>;cre organoid embedded in Matrigel and treated with 2  $\mu$ M tubacin. Imaged for 20 hours. Scale bar: 100  $\mu$ m. Timescale: min.